Skip to main content
SpringerLink
Log in

RETRACTED ARTICLE: The critical role of HMGA2 in regulation of EMT in epithelial ovarian carcinomas

  • Original Article
  • Published:
Tumor Biology

This article was retracted on 20 April 2017

Abstract

The high mobility group A2 (HMGA2), an oncofetal protein, was shown to play a role in tumor development and progression. However, the molecular and clinical role of HMGA2 in epithelial ovarian carcinomas (EOCs) is still unknown. In the present study, EOC cell line SKOV3 was subjected to in vitro assays. Here, our findings showed that HMGA2 was highly expressed in EOC cell line SKOV3. HMGA2 knockdown promoted cell apoptosis and the cleavage of caspase 3, and decreased the B cell lymphoma 2 (Bcl-2)/Bax ratio in SKOV3. Functionally, HMGA2 knockdown resulted in reduction of SKOV3 cell migration and invasion. Mechanically, HMGA2 knockdown affected the occurrence of EMT by increasing E-cadherin gene and protein expression and decreasing the gene and protein expression of N-cadherin, slug, and vimentin. At the same time, HMGA2 also repressed the expression of matrix metalloproteinase 2 (MMP2) and matrix metalloproteinase 9 (MMP9), which was consistent with the decreased invasion capacity. In conclusion, HMGA2 is associated with migration and invasiveness and regulates the progression of EMT in the development of EOC, and HMGA2 gene and protein may be a novel therapeutic target against EOC in the clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;S0140–6736:62146–7.

    Google Scholar 

  2. Harter P, Hilpert F, Mahner S, Heitz F, Pfisterer J, du Bois A. Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs. Expert Rev Anticancer Ther. 2010;10:81–8.

    Article  CAS  PubMed  Google Scholar 

  3. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Gynecologic Oncology Group Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–83.

    Article  CAS  PubMed  Google Scholar 

  4. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–96.

    Article  CAS  PubMed  Google Scholar 

  5. Chiappetta G, Ammirante M, Basile A, et al. The antiapoptotic protein BAG3 is expressed in thyroid carcinomas and modulates apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. J Clin Endocrinol Metab. 2007;92:1159–63.

    Article  CAS  PubMed  Google Scholar 

  6. Gentilella A, Passiatore G, Deshmane S, et al. Activation of BAG3 by Egr-1 in response to FGF-2 in neuroblastoma cells. Oncogene. 2008;27:5011–8.

    Article  CAS  PubMed  Google Scholar 

  7. Staibano S, Mascolo M, Benedetto M, et al. BAG3 protein delocalization in prostate carcinoma. Tumor Biol. 2010;31:461–9.

    Article  CAS  Google Scholar 

  8. Wang HQ, Meng X, Gao Y-Y, et al. Characterization of BAG3 cleavage during apoptosis of pancreatic cancer cells. J Cell Physiol. 2010;224:94–100.

    CAS  PubMed  Google Scholar 

  9. Suzuki M, Iwasaki M, Sugio A, et al. BAG3 (BCL2-associated athanogene 3) interacts with MMP-2 to positively regulate invasion by ovarian carcinoma cells. Cancer Lett. 2011;303:65–71.

    Article  CAS  PubMed  Google Scholar 

  10. Festa M, Del Valle L, Khalili K, et al. BAG3 protein is overexpressed in human glioblastoma and is a potential target for therapy. Am J Pathol. 2011;178:2504–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Rosati A, Graziano V, De Laurenzi V, et al. BAG3: a multifaceted protein that regulates major cell pathways. Cell Death Dis. 2011;7:141.

    Article  Google Scholar 

  12. Falco A, Festa M, Basile A, et al. BAG3 controls angiogenesis through regulation of ERK phosphorylation. Oncogene. 2012;31:5153–61.

    Article  CAS  PubMed  Google Scholar 

  13. Li N, Du ZX, Zong ZH, et al. PKC[delta]-mediated phosphorylation of BAG3 at Ser187 site induces epithelial-mesenchymal transition and enhances invasiveness in thyroid cancer FRO cells. Oncogene. 2012;32:4539–48.

    Article  PubMed  Google Scholar 

  14. He J, Gu D, Wu X, et al. Major causes of death among men and women in China. N Engl J Med. 2005;353:1124–34.

    Article  CAS  PubMed  Google Scholar 

  15. Pang RC, Joh J, Johnson P, et al. Biology of hepatocellular carcinoma. Ann Surg Oncol. 2008;15:962–71.

    Article  PubMed  Google Scholar 

  16. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med. 2002;8:S62–7.

    Article  CAS  PubMed  Google Scholar 

  17. Déry M-AC, Michaud MD, Richard DE. Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol. 2005;37:535–40.

    Article  PubMed  Google Scholar 

  18. De A, De A, Papasian C, et al. Extract induces autophagy and inhibits human ovarian cancer cell proliferation, angiogenesis, growth of mouse xenograft tumors. PLoS One. 2013;8:e72748.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Kim KW, Paul P, Qiao J, et al. Enhanced autophagy blocks angiogenesis via degradation of gastrin-releasing peptide in neuroblastoma cells. Autophagy. 2013;9:1579–90.

    Article  CAS  PubMed  Google Scholar 

  20. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell inter-actions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol. 1993;9:541–73.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We greatly thank other members of Yang Lab for valuable suggestions and writing.

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Gynaecology and Obstetrics, Affiliated Hospital of Shandong Academy of Medical Sciences, 38# Wuyingshan Road, 250031, Jinan, Shandong, China

    Junyuan Yan, Yan Liu & Yunyan Pan

  2. Department of Gynaecology and Obstetrics, The Third People’s Hospital of Jinan City, Jinan, Shandong, China

    Yanling Zhang, Wenshuang Shi & Cuili Ren

Authors
  1. Junyuan Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yanling Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wenshuang Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cuili Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yunyan Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yunyan Pan.

Additional information

The Publisher and Editor retract this article in accordance with the recommendations of the Committee on Publication Ethics (COPE). After a thorough investigation we have strong reason to believe that the peer review process was compromised.

An erratum to this article is available at http://dx.doi.org/10.1007/s13277-017-5487-6.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yan, J., Zhang, Y., Shi, W. et al. RETRACTED ARTICLE: The critical role of HMGA2 in regulation of EMT in epithelial ovarian carcinomas. Tumor Biol. 37, 823–828 (2016). https://doi.org/10.1007/s13277-015-3852-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-3852-x

Keywords

Search

Navigation